Tokai University Educational System;Nippon Zoki Pharmaceutical Co., Ltd.
发明人:
SAKAI Daisuke,HIRAYAMA Noriaki,SUYAMA Kaori
申请号：
AU2019224354
公开号：
AU2019224354A1
申请日:
2019.02.22
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The present invention addresses the problem of providing a low-molecular-weight compound (IL-17 activity inhibitor) having a more superior IL-17 activity-inhibiting ability than those of the conventional compounds. The IL-17RA inhibitor according to the present invention is a compound which can bind to interleukin 17 receptor A (IL-17RA) through a non-covalent interaction including at least one intermolecular interaction selected from the group that includes a van der Waals force acting among at least 13 amino acid residues selected from amino acid residues Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, Lys160, Pro164, Cys165, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys259, Asp262, Cys263, Leu264 and His266 contained in, for example, an extracellular domain of human IL-17RA and preferably consists of an ionic bond, a hydrogen bond, a CH-π interaction and a hydrophobic interaction each acting among specified amino acid residues among the above-mentioned amino acid residues in a space surrounded by the above-mentioned amino acid residues, and which has an activity to inhibit the binding of interleukin-17A (IL-17A) to IL-17RA originated from human or the like, or a pharmaceutically acceptable salt, solvate or prodrug of the compound.
